


**Imperial College**  
London

***T cell dynamics and retroviral infection***

Charles R M Bangham  
Department of Immunology,  
Wright-Fleming Institute  
Imperial College Faculty of Medicine

***In the race between microorganism and immune system, different immune weapons are used at different times***



# ***How do we know CTLs are necessary in the immune response to a virus?***

Three types of evidence:


- 1) deficiency of CTL number:
  - depletion of CTLs in mice by anti-CD8 antibody
  - CMI defect in humans: experiment of nature
  
- 2) deficiency of CTL function: knockout of beta-2 microglobulin gene in mice or perforin gene
  
- 3) passive ('adoptive') transfer of CD8+ T cells to a deficient recipient
  - mice
  - humans (HIV, EBV, CMV)

# CTLs select amino acid mutations in HIV-1 Nef


Immunology: Price *et al.*

*Proc. Natl. Acad. Sci. USA* 94 (1997) 1893

(a)



(b)



D. Price  
*et al*  
1997  
PNAS

# ***Human T-lymphotropic virus type 1 (HTLV-1)***


- infects 10-20 million people.
- endemic (1-20% of adults) in South America, Caribbean, Central Africa, southern Japan.
- 5% develop an aggressive T-cell leukaemia/lymphoma
- 1-2% develop a chronic inflammatory disease either of CNS, eyes, muscles, joints, lungs or skin.
- >90% remain healthy carriers of HTLV-1.

# ***HTLV-1 persistence and inflammatory disease***

Three main questions:

1. How does HTLV-1 persist?
2. How does it spread?
3. Why do some develop HAM/TSP, whereas most remain healthy carriers?

# *The proviral load of HTLV-1 correlates with the risk of HAM/TSP*



median proviral load  
(copies/100 PBMCs)


HAM/TSP: 5.4

asymptomatic: 0.34

Jeffery et al: PNAS  
(1999) **96**, 3848

# How is the high proviral load maintained?

Retroviruses replicate by two routes:






# *Evidence for latency of HTLV-1*

1. HTLV-1 varies little in sequence:

variability (Kabat-Wu)



Env

HIV-1

HTLV-1

Daenke et al. 1990: J. Virol. **64**, 1278


2. HTLV-1 mRNA and proteins are usually undetectable in PBMCs.
3. Virions are absent and plasma is non-infectious.

# ***'Standard model' of HTLV-1 persistence***

HTLV-1 is maintained by passive proliferation of provirus-containing lymphocytes.

A fraction of cells express HTLV-1, but too few to allow the immune response to make an impact on proviral load.

*Supported* by observation of large clones of HTLV-1<sup>+</sup> lymphocytes *in vivo*:



Wattel et al. 1995:  
*J. Virol.* **69**, 2863

# ***What is wrong with the 'standard model'?***

There is a persistent, strong immune response to HTLV-1.

- antibody: virus-specific IgM persists in many individuals
- cytotoxic T lymphocytes (CTLs) are chronically activated

*- does the CTL response make any impact?*

# ***CTLs reduce proviral load and risk of HAM/TSP***

- strong anti-Tax response exerts positive selection on *tax* gene<sup>1</sup>
- spontaneous Tax mutants escape CTLs<sup>2</sup>
- granzymes and perforin are more highly expressed in individuals with a low proviral load<sup>3</sup>
- CTLs spontaneously kill autologous HTLV-1<sup>+</sup> cells ex vivo<sup>4</sup>
- HLA-A2 and -C8 confer protection in s. Japan<sup>5</sup>
- High CTL avidity correlates with low proviral load and expression<sup>6</sup>

<sup>1</sup> Niewiesk et al. 1994: J. Virol. **68**, 6778; Kubota et al. 2007: J. Immunol. **178**, 5966

<sup>2</sup> Niewiesk et al. 1995: J. Virol. **69**, 2649

<sup>3</sup> Vine, Heaps et al. 2004: J. Immunol. **173**, 5121

<sup>4</sup> Hanon et al. 2000: Blood **95**, 1386 ; Asquith et al. 2005: J. Gen. Virol. **86**, 1515

<sup>5</sup> Jeffery et al. 1999: Proc. Nat. Acad. Sci. USA **96**, 3848

<sup>6</sup> Kattan, Rowan, Macnamara et al. 2009: J. Immunol. **182**, 5723

# ***Protective role of HLA class 1 indicates that CTLs limit HTLV-1 expression in vivo***

## **1. Possession of *either HLA-A\*02 or HLA-Cw\*08* :**

- reduced proviral load by 3-fold
- halved the odds of HAM/TSP

*HLA-A2 and HLA-Cw8 prevent 36% of potential HAM/TSP cases.*


## **2. HLA class 1 heterozygosity was associated with a lower proviral load.**

# How do HLA-A2 and -C8 protect against HTLV-1?


MacNamara, et al. 2010, PLoS Pathogens.

## Epitope prediction

200 peptides: 100 Tax, 100 HBZ




## Which HTLV-1 proteins bind best to A2 and Cw8?




**Conclusion:** protective alleles (A02 & C08) are those that bind HBZ strongly.

# ***HBZ – the only known transcript from the negative strand of the HTLV-1 provirus***



# ***Strong binding of HBZ peptides correlates with low proviral load***



**P = 0.016 (Spearman)**



# *Why is HBZ the critical target?*

HBZ inhibits expression of other HTLV-I genes  
=> Evade immune response


HBZ expression drives infected cell proliferation




**HBZ-specific  
CTLs**

Proviral load increases

# ***CTL protection is unrelated to immunodominance in HTLV-1 infection***



# *HIV-1 is controlled by CTLs*



GWAS with 1.3 million autosomal SNPs in 1712 individuals  
313 SNPs significantly associated with efficiency control of viral load

***Result: all 313 SNPs lie in the MHC class 1 region***

GWAS = genome-wide association study  
SNP = single nucleotide polymorphism

International HIV Controllers Study 2010  
Science **330**, 1551-1557

# ***Conclusions (1): CTL response***



1. CTL response to HBZ determines the outcome of HTLV-1 infection
2. Strength of CTL response to Tax is *consequence, not cause*, of efficient host control of HTLV-1
3. HLA Class 1 protection prevents ~50% of cases of HAM/TSP
4. Frequency, phenotype\* and function\*\* of CTLs cannot be used to measure CTL effectiveness in persistent infections

\* phenotype: e.g. PD-1 expression


\*\* function: e.g. “polyfunctionality” – ability to carry out >1 effector mechanism (CTL lysis; IFN; IL-2; etc.)

# Questions raised by clonal proliferation of HTLV-1+ T cells

- how many clones are present in each host?
- what determines the size of a clone?
- how can we define and measure 'clonality'?
- what is the relationship between clonality and:
  - proviral load?
  - disease status – can we predict ATL?
  - immune surveillance?
  - intercurrent infections – Strongyloidiasis; TB; infectious dermatitis?



Meekings et al. 2008:  
PLoS Path. 4, e1000027



# ***Current view of HTLV-1 clonality in vivo***

- **number of infected T-cell clones in chronic phase:**
  - unknown with precision, but believed to lie between 10 and 100 on the basis of Southern blot analysis.
- **oligoclonality**
  - appears higher in HAM/TSP than in asymptomatic carriers (Southern blot)

# *Hypothesis*

***Genomic integration site determines clonal fitness and pathogenic potential of a HTLV-1<sup>+</sup> T cell clone***

- transcriptional activity of flanking DNA
- identity ('ontology') of flanking host genes.

*Required:* a technique to map proviral integration sites in PBMCs:

- sensitive
- high-throughput
- quantitative


# 1. How many provirus copies/cell?

## Method

CD4<sup>+</sup> HTLV-1<sup>+</sup> T-cell clones isolated by limiting dilution in presence of HTLV-1 integrase inhibitor (raltegravir) to minimize secondary infection

HTLV-1 proviral integration sites mapped & quantified

## Results



**Conclusion:** HTLV-1-infected cells carry a single provirus in vivo



## 2. Targeting of HTLV-1 integration site

### Proviral integration is not random


Genomic attributes tested:

- histone marks
- **transcription factor binding sites**
- DNase 1 hypersensitive sites
- CpG islands
- gene density
- proximity to genes
- gene ontology
- nucleosomes
- chromatin remodelling factors

Targeting effects are


- short-range (<1kb)
- typically symmetrical

Anat Melamed, unpublished



# HTLV-1 integration targeting to sites of host DNA-binding proteins: summary



integration is favoured symmetrically, upstream and downstream of sites




Independent, significant correlates of integration targeting (logistic regression).

A. Melamed, unpublished

# What determines spontaneous proviral expression?




# Influence of flanking host genome on Tax expression: summary



**Asymmetry of effects (upstream/downstream)  
contrasts with integration targeting.**

# 4. Spontaneous Tax expression depends on orientation relative to flanking host gene


## Proviral orientation



same-sense orientation *suppresses* Tax expression:

$$p = 4.6 \times 10^{-15}$$


$$OR = 1.34$$



## Clone abundance

- *inversely* correlated with Tax expression

$$p = 8 \times 10^{-33}$$




## 5. How many HTLV-1<sup>+</sup> clones in one host?

*Previous estimates:*

~ 10 to 100 in a typical AC  
or HAM patient

~ 1 in a patient with ATLL



# Estimation of total number of HTLV-1+ clones in one host

Laydon 2012, unpublished

- Fit many models (~70) to all patients' datasets and subsets thereof
- Score models against following criteria:

## 1) Goodness of fit

## 2) Accuracy


From all subsample sizes, model must “predict” true no. clones in total

## 3) Similarity

Area between curves extrapolated from all subsamples must be minimal

## 4) Plausibility


More cells should not result in fewer clones



# *New method surpasses ecological predictors*

estimated total number of clones

*new method*




Ecological methods fail  
*true value*

Data on representative patient with HAM/TSP

number of infected cells sampled



# How many HTLV-1<sup>+</sup> T-cell clones in one host?



## Number of clones

*observed* (in ≤10μg DNA) 200 to 3500

*estimated total in circulation* (DivE) 10<sup>3</sup> to 10<sup>6</sup> (mean ~ 60000)

# Conclusions


	<u>Previous belief</u>	<u>New conclusion</u>
<i>Total clone number</i>	10 to 100	$10^3$ to $10^6$
<i>HAM/TSP</i>	associated with oligoclonal proliferation	associated with greater <i>number</i> of clones
<i>Targeting of integration</i>	random	targeted to specific transcription factor binding sites
<i>Proviral orientation</i>	same-sense <i>favours</i> Tax	same-sense <i>suppresses</i> Tax
<i>Clone abundance</i>	associated with Tax <sup>+</sup>	associated with Tax <sup>-</sup>
<i>Proviral copy number</i>	multiple	one copy/cell

## ***If HTLV-1 is expressed in vivo, where are the virus particles?***


- serum from HTLV-1-infected people is not infectious; HTLV-1 is usually undetectable by EM and by PCR
- only ~1 in  $10^5$  to  $10^6$  HTLV-I virions (from a cell line) is infectious
- cell contact is required for efficient spread of HTLV-I, both between individuals (transfer of lymphocytes) and *in vitro*

# *HTLV-1 is transmitted directly between cells across an organized cell-cell contact – the virological synapse*


Gag protein complexes (red) polarize to the cell-cell contact area




- which contains organized adhesion domains (green)



Gag is then transferred with the HTLV-1 genome to the target cell



# *HTLV-1 Gag<sup>+</sup> particles are trapped between membranes at the VS*




a  
a  
a  
a  
a  
a  
a  
a

Majorovits,  
Nejmeddine  
et al, 2008

# How does HTLV-1 persist and cause disease?

## Quality of the CTL response

FoxP3<sup>+</sup>CD4<sup>+</sup> T cells



HTLV-1 antigen-specific CTL-mediated immune responses




Host HLA class I genotype (epitope recognition)  
Functional avidity of antigen recognition  
Per cell expression levels of cytotoxic genes  
KIR2DL2 genotype

## Antigen load and clonal abundance

↑ Number of HTLV-1<sup>+</sup> clones

Tax: virological synapse



Expression of proviral genes (viral antigens)

HBZ (Tax) proliferation

HTLV-1 integration: transcription factor binding sites

↑ Clone abundance

## Outcome of infection

